A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.

被引：1
|
作者：
Hellmann, Matthew David
Shimizu, Toshio
Doi, Toshihiko
Hodi, F. Stephen
Rottey, Sylvie
Aftimos, Philippe Georges
Liu, Zhuqing Tina
de Mendizabal, Nieves Velez
Szpurka, Anna M.
Piao, Yongzhe
Vangerow, Burkhard
Gandhi, Leena
Leow, Ching Ching
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] NCCH, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Ghent Univ Hosp, Heymans Inst Pharmacol, Ghent, Belgium
[7] Univ Libre Bruxelles, Inst Jules Bordet, Med Oncol Clin, Brussels, Belgium
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
[9] Eli Lilly Japan KK, Kobe, Hyogo, Japan
[10] Eli Lilly & Co, Bad Homburg, Germany
[11] NYU Perlmutter Canc Ctr, New York, NY USA
[12] Eli Lilly & Co, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS2654
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2654
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
    Hellmann, Matthew D.
    Bivi, Nicoletta
    Calderon, Boris
    Shimizu, Toshio
    Delafontaine, Brant
    Liu, Zhuqing Tina
    Szpurka, Anna M.
    Copeland, Victoria
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe
    Piao, Yongzhe
    Gandhi, Leena
    Galvao, Violeta Regnier
    Leow, Ching Ching
    Doi, Toshihiko
    CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2773 - 2781
  • [2] Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors
    Liu, Jiajian
    Zhou, Caicun
    Li, Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Phase 1 study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in patients with advanced solid tumors or lymphoma
    Liu, Jiajian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
    Harding, James J.
    Moreno, Victor
    Bang, Yung-Jue
    Hong, Min Hee
    Patnaik, Amita
    Trigo, Jose
    Szpurka, Anna M.
    Yamamoto, Noboru
    Doi, Toshihiko
    Fu, Siqing
    Calderon, Boris
    de Mendizabal, Nieves Velez
    Calvo, Emiliano
    Yu, Danni
    Gandhi, Leena
    Liu, Zhuqing Tina
    Galvao, Violeta Regnier
    Leow, Ching Ching
    de Miguel, Maria J.
    CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2168 - 2178
  • [6] Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors.
    Xu, Rui-hua
    Zhao, Hongyun
    Wei, Xiao-Li
    Zhang, Yang
    Wang, Feng
    Wang, Zhiqiang
    Wang, Fenghua
    Li, Yu-Hong
    Zou, Ben-Yan
    Zhu, Xiaomin
    Yu, Wencheng
    Zhou, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] A phase I study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
    Gordon, Michael S.
    Hamid, Omid
    Powderly, John
    Anderson, Maria
    Fine, Gregg
    Mokatrin, Ahmad
    Kowanetz, Marcin
    Maya, Leabman
    Irving, Bryan A.
    Chen, Daniel S.
    Hodi, F. Stephen
    CANCER RESEARCH, 2013, 73 (08)
  • [8] A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.
    Herbst, Roy S.
    Gordon, Michael S.
    Fine, Gregg Daniel
    Sosman, Jeffrey Alan
    Soria, Jean-Charles
    Hamid, Omid
    Powderly, John D.
    Burris, Howard A.
    Mokatrin, Ahmad
    Kowanetz, Marcin
    Leabman, Maya
    Anderson, Maria
    Chen, Daniel S.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study
    Ruan, Dan-Yun
    Wei, Xiao-Li
    Liu, Fu-Rong
    Hu, Xi-Chun
    Zhang, Jian
    Ji, Dong-Mei
    Huang, Ding-Zhi
    Zhao, Yan-Qiu
    Pan, Hong-Min
    Liao, Wang-Jun
    Yang, Kun-Yu
    Xu, Nong
    Lu, Xiao-Xiao
    Chen, Yu-Ling
    Zhang, Wen
    Zhou, Hui
    Zhao, Hong-Yun
    Xu, Rui-Hua
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [10] Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors
    Falchook, Gerald Steven
    LoRusso, Patricia
    Goldman, Jonathan W.
    El-Khoueiry, Anthony B.
    Tolcher, Anthony W.
    Xing, Yan
    Henry, Jason Timothy
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae-Yong
    Kim, Hye Ryun
    Hong, Min Hee
    Kim, Min Hwan
    Lee, Dae Ho
    Lee, SangMi
    Jeon, JuYeun
    Hayslip, John W.
    Xu, Cong
    Garon, Edward B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345